Topoisomerase II poisoning by ICRF-193

被引:78
作者
Huang, KC
Gao, HL
Yamasaki, EF
Grabowski, DR
Liu, SJ
Shen, LL
Chan, KK
Ganapathi, R
Snapka, RM
机构
[1] Ohio State Univ, Coll Med, Dept Radiol, Columbus, OH 43210 USA
[2] Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA
[3] Cleveland Clin Fdn, Taussig Canc Ctr, Cleveland, OH 44195 USA
[4] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA
[5] Abbott Labs, Abbott Pk, IL 60064 USA
关键词
D O I
10.1074/jbc.M104383200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Antineoplastic bis(dioxopiperazine)s, such as meso-2,3-bis(2,6-dioxopiperazin-4-yl)butane (ICRF-193), are widely believed to be only catalytic inhibitors of topoisomerase II. However, topoisomerase inhibitors have little or no antineoplastic activity unless they are topoisomerase poisons, a special subclass of topoisomerase-targeting drugs that stabilize topoisomerase-DNA strand passing intermediates and thus cause the topoisomerase to become a cytotoxic DNA-damaging agent. Here we report that ICRF-193 is a very significant topoisomerase II poison. Detection of topoisomerase II Poisoning by ICRF-193 required the use of a chaotropic protein denaturant in the topoisomerase poisoning assays. ICRF-193 caused dose-dependent cross-linking of human topoisomerase II beta to DNA and stimulated topoisomerase II beta -mediated DNA cleavage at specific sites on P-32-end-labeled DNA. Human topoisomerase Ha-mediated DNA cleavage was stimulated to a lesser extent by ICRF-193. In vivo experiments with MCF-7 cells also showed the requirement of a chaotropic protein denaturant in the assays and selectivity for the beta -isozyme of human topoisomerase II. Studies with two topoisomerase II beta -negative cell model systems confirmed significant topoisomerase II poisoning by ICRF-193 in the wild type cells and were consistent with beta -isozyme selectivity. Common use of only the detergent, SDS, in assays may have led to failure to detect topoisomerase II poisoning by ICRF-193 in earlier studies.
引用
收藏
页码:44488 / 44494
页数:7
相关论文
共 37 条
[1]   BIOCHEMICAL STUDIES ON GROWTH-INHIBITORY BISDIOXOPIPERAZINES .1. EFFECT ON DNA, RNA AND PROTEIN SYNTHESIS IN MOUSE-EMBRYO FIBROBLASTS [J].
CREIGHTON, AM ;
BIRNIE, GD .
INTERNATIONAL JOURNAL OF CANCER, 1970, 5 (01) :47-+
[2]   ANTITUMOUR ACTIVITY IN A SERIES OF BISDIKETOPIPERAZINES [J].
CREIGHTON, AM ;
HELLMANN, K ;
WHITECROSS, S .
NATURE, 1969, 222 (5191) :384-+
[3]  
CREIGHTON AM, 1970, PROGR ANTIMICROB ANT, V1, P167
[4]  
FELIX CA, 1995, CANCER RES, V55, P4287
[5]   XK469, a selective topoisomerase IIβ poison [J].
Gao, HL ;
Huang, KC ;
Yamasaki, EF ;
Chan, KK ;
Chohan, L ;
Snapka, RM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (21) :12168-12173
[6]  
Gao HL, 2000, CANCER RES, V60, P5937
[7]   A QSAR STUDY COMPARING THE CYTOTOXICITY AND DNA TOPOISOMERASE-II INHIBITORY EFFECTS OF BISDIOXOPIPERAZINE ANALOGS OF ICRF-187 (DEXRAZOXANE) [J].
HASINOFF, BB ;
KUSCHAK, TI ;
YALOWICH, JC ;
CREIGHTON, AM .
BIOCHEMICAL PHARMACOLOGY, 1995, 50 (07) :953-958
[8]   Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II [J].
Hasinoff, BB ;
Kuschak, TI ;
Creighton, AM ;
Fattman, CL ;
Allan, WP ;
Thampatty, P ;
Yalowich, JC .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (12) :1843-1853
[9]   STEREOCHEMISTRY OF THE ANTI-TUMOR AGENT 4,4'-(1,2-PROPANEDIYL)BIS(4-PIPERAZINE-2,6-DIONE) - CRYSTAL AND MOLECULAR-STRUCTURES OF THE RACEMATE (ICRF-159) AND A SOLUBLE ENANTIOMER (ICRF-187) [J].
HEMPEL, A ;
CAMERMAN, N ;
CAMERMAN, A .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1982, 104 (12) :3453-3456
[10]   BIOLOGICAL PROPERTIES OF ICRF-159 AND RELATED BIS(DIOXOPIPERAZINE) COMPOUNDS [J].
HERMAN, EH ;
WITIAK, DT ;
HELLMANN, K ;
WARAVDEKAR, VS .
ADVANCES IN PHARMACOLOGY AND CHEMOTHERAPY, 1982, 19 :249-290